Jiu Fang Pharmaceutical

Anhui Jiufang Pharmaceutical Co., Ltd. (Jiufang Pharmaceutical), established in 1993, is a national high-tech enterprise integrating medicinal material cultivation, drug research and development, production, and sales. Headquartered in Bozhou, Anhui Province, the company focuses on the R&D and production of modern traditional Chinese medicines (TCM) for chronic and difficult diseases, particularly in cardiovascular, digestive, heat-clearing, and nutritional health areas. Its core commercial products include Geketongluo Capsule for ischemic stroke and Hudi Enteric-coated Capsule for ulcerative colitis. Jiufang Pharmaceutical is also developing Vitexin for Injection, a national Class I new drug derived from hawthorn leaves, currently in Phase 2 clinical trials for cardiovascular diseases. In 2023, the company was acquired by Hefei Lifeon Pharmaceutical Co., Ltd., which holds a 51% controlling stake.